Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN REDITABS versus CYPROHEPTADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN REDITABS versus CYPROHEPTADINE HYDROCHLORIDE.
CLARITIN REDITABS vs CYPROHEPTADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
10 mg orally once daily.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
None Documented
None Documented
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Category C
Category A/B
Antihistamine
Antihistamine